Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

Coya Therapeutics expects to release data from the biomarker analyses of COYA 302 and publish the full results from the trial in a peer-reviewed journal in the second half of the year.

Coya Therapeutics Announces Plans for FDA Discussion on ALS Agent COYA 302

Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.

Standard and Nonstandard Physical Therapy Show Similar Effectiveness for Parkinson Disease

Videos

The associate professor of neurology at Vanderbilt University Medical Center discussed the progress in stroke care, focusing on ischemic strokes and cerebral hemorrhages, and their connection with vascular diseases and cognitive disorders. [WATCH TIME: 3 minutes] 

Advancements in Stroke Care, Ischemic Stroke, and Cerebral Hemorrhages: Matthew Schrag, MD, PhD

Between ages 65 to 69, gene carriers of APOE ε4 could detect an average of about 3.2 of the smells presented, compared with about 3.9 smells for noncarriers of the gene variant.

Declined Odor Sensitivity Observed in APOE ε4 Carriers 

Slideshows

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

IJMSC September/October 2023 Highlights

, has been with the team since September 2022. Follow her on Twitter 

Leigh Charvet, PhD, professor of neurology at the NYU Grossman School of Medicine, talked about a trial that aims to address cognitive impairment in patients with long COVID through a unique, remote, and home-based treatment approach.

Targeting Cognitive Impairment of Long COVID With Brain Stimulation 

A panel of neurology experts detailed the importance that community leadership and creating a positive environment can do for patients with rare neurologic disorders [WATCH TIME: 5 minutes]

Role of Advocacy Organizations in Creating Safe Spaces for Rare Disorders

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

Ataxia

MDS 2023

NMOSD

Narcolepsy

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

The News Network video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases.

1rem

AAN 2020 Annual Meeting: Epilepsy Highlights 

GWPCARE5 Trial Update: Lennox Gastaut Syndrome

GWPCARE5 Trial Update: Dravet Syndrome

AAN 2020 Data: Neurostimulation and Adjunctive ZX008

AAN 2020 Clinical Trial Data: Uncontrolled Focal Seizures 

Cannabidiol for Lennox-Gastaut Syndrome and Dravet Syndrome

Cannabidiol Treatment for Tuberous Sclerosis Complex

Fenfluramine for Sunflower Syndrome

 Epilepsy Treatment Outlook

Long-Term Data for Cannabidiol in Lennox-Gastaut Syndrome

Long-Term Data for Cannabidiol in Dravet Syndrome

Brivaracetam in Children With PGS or Mixed Seizure Types

FREEDOM Trial: Perampanel Monotherapy for Recurrent POS

Future Directions in Epilepsy Management: Closing the Gap